TL;DR - I’m asking the FDA and Novartis to update Everolimus’s labeling for heart-transplant patients so insurers can’t deny or question it when transplant doctors say it’s medically necessary. Recently, I faced a devastating challenge when my insurance company, Anthem, denied coverage for Everolimus — a medication I urgently need to protect my heart transplant. Their reasoning was deeply frustrating: Everolimus is not FDA-approved for heart transplants, only for kidney and liver transplants, and the U.S. label even states that it is “not recommended in heart transplant patients.” Because of this labeling, Anthem claimed it “isn’t medically necessary” for me as a heart-transplant recipient. I came so close to running out of Everolimus that my donor’s mom was prepared to pay out of pocket so I wouldn’t lose the medication protecting her son’s heart. No donor family should ever be put in that position. But for many heart transplant patients like me, Everolimus is not optional. It is life-preserving. Heart transplant recipients rely on precise combinations of immunosuppressive medications to prevent rejection and protect the new heart. Everolimus has been shown in multiple studies to reduce rejection, preserve kidney function, and slow the progression of cardiac allograft vasculopathy (CAV) — one of the leading causes of long-term transplant failure. Despite these benefits, the FDA has never updated Everolimus’s approval to include heart transplants, and the label language has not kept up with modern transplant practice. This leaves patients trapped in a dangerous gap: the medication is scientifically supported and used by transplant teams around the world for carefully selected heart-transplant patients, yet U.S. patients can be forced to fight insurance denials simply because the label has not caught up with real-world evidence. In a small anonymous survey I conducted of heart-transplant patients on Everolimus, the picture is mixed: some have not yet had coverage problems, while others (including me) have already faced denials or very high out-of-pocket costs. Even if it doesn’t happen to every patient, the current label gives insurers a powerful excuse to question or block Everolimus when a transplant specialist believes it is medically necessary. No insurance company should be allowed to override a transplant cardiologist and deny the anti-rejection medication they judge to be the safest and most effective option for a specific patient. We are calling on the FDA and Novartis to review the growing body of clinical data and real-world experience and to update Everolimus’s indication and labeling to better reflect its use in heart transplant recipients. Doing so would protect patients from life-threatening denials and make it harder for insurers to hide behind outdated wording like “not recommended in heart transplant patients” when transplant teams strongly disagree. Heart transplant patients deserve the same access and protections offered to other organ recipients. No patient should have to battle insurance companies for a medication that keeps their transplanted heart beating — and no donor family should have to watch that fight, knowing the organ they gave could be put at risk. ⸻ 🩺 Scientific Evidence Supporting Everolimus in Heart Transplantation Kobashigawa et al., 2013 (J Heart Lung Transplant) Everolimus significantly reduced cardiac allograft vasculopathy progression compared to MMF. 👉 https://pubmed.ncbi.nlm.nih.gov/24621971 Arora et al., 2012 (J Heart Lung Transplant) Improved kidney function in stable heart transplant patients switched to Everolimus with lower calcineurin-inhibitor doses. 👉 https://pubmed.ncbi.nlm.nih.gov/22333403/ Eisen et al., 2003 (New England Journal of Medicine) A major randomized trial showing comparable rejection control and less coronary artery disease in Everolimus-treated heart transplant patients. 👉 https://www.nejm.org/doi/full/10.1056/NEJMoa02217 SCHEDULE Trial, 2017 (Circulation: Heart Failure) Early Everolimus use with cyclosporine withdrawal led to less CAV progression and better kidney outcomes. 👉 https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.117.004050 TEAMMATE Trial, 2023 (NHLBI-Funded, Pediatric Study) Showed similar rejection control using Everolimus + low-dose tacrolimus, with better kidney protection and fewer infections. 👉 https://pubmed.ncbi.nlm.nih.gov/36745220/ ⸻ ❤️ Call to Action We urgently call on Novartis to collaborate with the U.S. Food and Drug Administration in submitting updated clinical data and real-world experience supporting Everolimus (Zortress/Afinitor) for heart transplant recipients and to clarify labeling so that heart-transplant use is no longer automatically treated as “not recommended.” Everolimus has demonstrated: • reduced rejection • protection of kidney function • slowed development of cardiac allograft vasculopathy Approving and clearly recognizing this medication for appropriate heart transplant use would save lives, prevent harmful denials, and ensure that patients are not left fighting bureaucracy for the drugs that keep their hearts beating.